ストックスクリーナーアプリを入手
38.80
0.69%
-0.27
アフターアワーズ：
39.06
0.26
+0.67%
前日終値:
$39.07
開ける：
$38.32
24時間の取引高:
1.09M
Relative Volume:
0.64
時価総額：
$7.13B
収益：
$520.18M
当期純損益:
$-348.13M
株価収益率:
-20.21
EPS:
-1.92
ネットキャッシュフロー:
$-176.18M
1週間 パフォーマンス:
-10.52%
1か月 パフォーマンス:
+6.92%
6か月 パフォーマンス:
+1.84%
1年 パフォーマンス:
-29.45%
1日の値動き範囲:
$38.10
$39.27
1週間の範囲:
$38.10
$43.71
52週間の値動き範囲:
$27.34
$59.62
Legend Biotech Corp Adr Stock (LEGN) Company Profile
LEGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
38.80 | 7.19B | 520.18M | -348.13M | -176.18M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-06-17 | 開始されました | Truist | Buy |
| 2024-05-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-05-23 | 開始されました | Deutsche Bank | Buy |
| 2024-04-17 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | Raymond James | Outperform |
| 2023-12-19 | 開始されました | Scotiabank | Sector Perform |
| 2023-11-06 | 開始されました | Goldman | Buy |
| 2023-05-25 | 開始されました | William Blair | Mkt Perform |
| 2023-05-22 | 開始されました | Daiwa Securities | Buy |
| 2023-03-29 | 開始されました | H.C. Wainwright | Buy |
| 2023-03-24 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-11-02 | 開始されました | Evercore ISI | Outperform |
| 2022-11-01 | 開始されました | Cowen | Outperform |
| 2022-10-31 | 開始されました | Guggenheim | Neutral |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-03-15 | 開始されました | Barclays | Overweight |
| 2022-01-31 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | 開始されました | Piper Sandler | Overweight |
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2020-07-01 | 開始されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Legend Biotech Corp Adr (LEGN) 最新ニュース
Brokerages Set Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Price Target at $73.33 - Defense World
Bank of New York Mellon Corp Has $4.55 Million Stake in Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) - Defense World
HC Wainwright Forecasts Legend Biotech Q2 Earnings - Defense World
Legend Biotech’s (LEGN) Buy Rating Reiterated at HC Wainwright - Defense World
Q1 EPS Estimates for Legend Biotech Raised by HC Wainwright - Defense World
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains? - Yahoo Finance
Legend Biotech’s SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com India
Legend Biotech’s SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. Wainwright reiterates Buy rating on Legend Biotech stock after strong CARVYKTI sales - Investing.com India
Goldman Sachs reiterates buy rating on Legend Biotech stock after strong Carvykti sales - Investing.com India
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Shares Acquired by GAMMA Investing LLC - Defense World
Legend Biotech stock price target lowered to $54 at UBS on growth concerns - Investing.com
Legend Biotech stock maintains Buy rating as FDA eases CARVYKTI restrictions - Investing.com
Legend Biotech’s SWOT analysis: carvykti’s strong performance drives stock potential By Investing.com - Investing.com South Africa
Legend Biotech’s SWOT analysis: carvykti’s strong performance drives stock potential - Investing.com India
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Barchart.com
Oracle and GameStop Headline Market Cap Stock Movers on Thursday By Investing.com - Investing.com South Africa
Eli Lilly, General Electric among Tuesday’s market cap stock movers By Investing.com - Investing.com India
Eli Lilly, General Electric among Tuesday’s market cap stock movers - Investing.com
CARVYKTI shows lasting impact in multiple myeloma treatment By Investing.com - Investing.com South Africa
RBC Capital maintains outperform rating on Legend Biotech stock By Investing.com - Investing.com South Africa
RBC Capital maintains outperform rating on Legend Biotech stock - Investing.com India
BMO Capital reaffirms outperform rating on Legend Biotech stock By Investing.com - Investing.com South Africa
BMO Capital reaffirms outperform rating on Legend Biotech stock - Investing.com India
Legend Biotech’s SWOT analysis: carvykti drives growth as stock faces competition - Investing.com India
RBC Capital maintains Legend Biotech at outperform with $78 target By Investing.com - Investing.com South Africa
RBC Capital maintains Legend Biotech at outperform with $78 target - Investing.com
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday By Investing.com - Investing.com South Africa
AbbVie, Nvidia, and Exelixis Lead Market Cap Stock Movers on Wednesday - Investing.com
Legend Biotech stock holds $62 target, solid Carvykti sales growth - Investing.com India
Legend Biotech stock holds $62 target, solid Carvykti sales growth By Investing.com - Investing.com UK
Truist cuts Legend Biotech stock target to $71, maintains buy rating - Investing.com India
Raymond James maintains Legend Biotech Outperform rating - Investing.com
Raymond James maintains Legend Biotech Outperform rating By Investing.com - Investing.com UK
Earnings call transcript: Legend Biotech Q1 2025 sees strong CARVICTI sales boost - Investing.com India
Legend Biotech Q1 2025 slides: CARVYKTI sales surge 135% as path to profitability clarifies - Investing.com India
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights - GlobeNewswire Inc.
Stock Surge: Legend Biotech Corp ADR (LEGN) Closes at 31.37, Marking a -6.08 Increase/Decrease - DWinneX
What Makes Legend Biotech (LEGN) a New Buy Stock - Yahoo Finance
Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet - Yahoo Finance
Top investors say Legend Biotech Corp ADR (LEGN) ticks everything they need - Sete News
LEGN stock rated a Buy by Redburn Atlantic - knoxdaily.com
Taking a look at what insiders are doing to gauge the Legend Biotech Corp ADR (LEGN)’s direction - knoxdaily.com
Selling Buzz: Graphjet Technology [GTI] 10% Owner SURIA SUKSES ENGINEERING SDN B sells 2,490,517 shares of the company – Knox Daily - knoxdaily.com
UP Fintech Holding Ltd ADR [TIGR] Records 200-Day SMA of $6.22 - knoxdaily.com
UEC Stock Sees Surge of Approximately 9.34% in Last Five Days - knoxdaily.com
Vir Biotechnology Inc [VIR] Records 200-Day SMA of $8.24 - knoxdaily.com
Arm Holdings plc. ADR [ARM] Officer makes an insider purchase of 9,220 shares worth 1.41 million. - knoxdaily.com
Valero Energy Corp [VLO] Records 200-Day SMA of $134.80 - knoxdaily.com
KE Holdings Inc ADR [BEKE] Records 200-Day SMA of $18.54 - knoxdaily.com
Celestica, Inc [NYSE: CLS] Sees Increase in Stock Value - knoxdaily.com
Legend Biotech Corp Adr (LEGN) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
0.15%
大文字化:
|
ボリューム (24 時間):